Related Experiment Video
Updated: Aug 19, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
Zidovudine in primary Sjögren's syndrome
S D Steinfeld1, P Demols, J P Van Vooren
1Division of Rheumatology, Erasmus Academic Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Objective:
To evaluate the efficacy of the administration of zidovudine (AZT), an antiretroviral drug, in patients with primary Sjögren's syndrome (SS).
Methods:
Seven female patients (age 57 +/- 8.6 yr) with primary SS were enrolled in an open, uncontrolled trial of AZT (250 mg b.i.d.) for the treatment of primary SS. The efficacy variables were oral and ocular dryness symptoms, fatigue, tender points, physician's and patient's global assessments (GA), ocular function tests (fluorescein tear break-up time, Schirmer's test, Rose Bengal staining) and laboratory parameters [erythrocyte sedimentation rate (ESR), serum IgG, IgA and IgM].
Results:
A significant improvement was observed in all subjective manifestations, as well as the objective parameters of ocular dryness. The treatment was well tolerated, except for mild and transitory gastrointestinal disturbances in 6/7 patients. Laboratory parameters did not change significantly. The clinical benefit persisted in 5/7 patients 1 month after the end of therapy.
Conclusion:
AZT seems to be effective and well tolerated in patients with primary SS.
More Related Videos
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Subviral Agents
Cytomegalovirus Disease
Genital Herpes
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors

